{{Rsnum
|rsid=12435920
|Gene=SLC24A4
|Chromosome=14
|position=92383122
|Orientation=plus
|GMAF=0.3999
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC24A4
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 23.0 | 46.9 | 30.1
| HCB | 0.0 | 6.6 | 93.4
| JPT | 0.0 | 0.9 | 99.1
| YRI | 53.7 | 38.1 | 8.2
| ASW | 38.6 | 47.4 | 14.0
| CHB | 0.0 | 6.6 | 93.4
| CHD | 0.9 | 4.6 | 94.4
| GIH | 9.9 | 44.6 | 45.5
| LWK | 51.4 | 38.1 | 10.5
| MEX | 7.0 | 49.1 | 43.9
| MKK | 48.1 | 43.6 | 8.3
| TSI | 23.8 | 52.5 | 23.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12435920
|Name_s=
|Gene_s=SLC24A4
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00002. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109458
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12435920
|overall_frequency_n=61
|overall_frequency_d=128
|overall_frequency=0.476562
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=55
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}